Back to Directory Kaylee Lee Email Kaylee.Lee@ucsf.edu Institution University of California, San Francisco Request an Update Affiliated Studies IMPAACT 2024 : Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age with and without HIV. DAIDS Number 38747 Research Area Tuberculosis Study Status Open to Accrual
IMPAACT 2024 : Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age with and without HIV. DAIDS Number 38747 Research Area Tuberculosis Study Status Open to Accrual
